Welcome to our dedicated page for Bio-Key Intl SEC filings (Ticker: BKYI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BIO-key International, Inc. filings document the formal disclosures of an IAM and biometric authentication company, including operating results and financial condition in Form 8-K reports, press-release exhibits, and the company’s Form 12b-25 notice for a delayed annual report. The records also capture disclosures tied to software license renewals, hardware revenue activity, and cash-position commentary.
Proxy and current-report filings cover stockholder voting, certificate amendments, and material modifications to security-holder rights related to the 1-for-10 reverse stock split. The filing record also includes Nasdaq continued-listing notices tied to periodic-report timing, capital-structure disclosures, governance procedures, and meeting mechanics for common stockholders.
BIO-key International, Inc. notified the SEC it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company says compilation and review of certain financial statement information could not be completed without unreasonable effort and expense and expects to file on or before the fifth calendar day following the prescribed due date.
The filing reiterates preliminary expected results for the quarter: revenue $2,145,533, gross profit $1,769,233, and basic and diluted loss per share $(0.15), each compared to the prior-year quarter.
BIO-key International reported stronger Q1 2026 results, with revenue rising 35% to $2,145,533 from $1,607,159 a year earlier and its net loss narrowing to $165,036 from $736,545. Growth was driven by a 24% increase in license fees to $1,365,893 and hardware revenue more than doubling to $531,256, supported by large renewals and expanded deployments.
Gross profit increased to $1,769,233, maintaining a strong 82% gross margin. Operating expenses fell 4% to $1,886,946, improving operating loss to $117,713. Management stated it expects Q2 2026 profitability based on an anticipated 65% revenue increase and highlighted traction with foreign defense and financial customers. The company also noted its shares are currently suspended from trading on the Nasdaq Capital Market and are quoted on OTC Markets under BKYI.
BIO-key International, Inc. is reporting that its common stock will be suspended from trading on the Nasdaq Capital Market and move to OTC Markets. Nasdaq staff notified the company that it failed to regain compliance with the $1.00 minimum bid price requirement for 10 consecutive business days by May 4, 2026 and that it has not yet filed its Form 10-K for the year ended December 31, 2025.
Trading on Nasdaq is scheduled to be suspended at the close on May 12, 2026, with quotation on OTC Markets under the symbol “BKYI” beginning May 13, 2026. BIO-key plans to request a hearing before a Nasdaq Hearings Panel and is taking measures, including engaging listing consultants, to seek reinstatement, but there is no assurance it will regain compliance or return to Nasdaq.
BIO-key International, Inc. is reporting that its common stock will be suspended from trading on the Nasdaq Capital Market and move to OTC Markets. Nasdaq staff notified the company that it failed to regain compliance with the $1.00 minimum bid price requirement for 10 consecutive business days by May 4, 2026 and that it has not yet filed its Form 10-K for the year ended December 31, 2025.
Trading on Nasdaq is scheduled to be suspended at the close on May 12, 2026, with quotation on OTC Markets under the symbol “BKYI” beginning May 13, 2026. BIO-key plans to request a hearing before a Nasdaq Hearings Panel and is taking measures, including engaging listing consultants, to seek reinstatement, but there is no assurance it will regain compliance or return to Nasdaq.
BIO-key International, Inc. is implementing a 1-for-10 reverse stock split of its common stock, reducing the total outstanding shares from approximately 10,852,118 to approximately 1,085,212. The reverse split becomes effective at 5:00 p.m. Eastern Time on April 29, 2026, with split-adjusted trading on the Nasdaq Capital Market beginning April 30, 2026 under a new CUSIP number 09060C606.
The number of authorized shares and the par value per share remain unchanged. No fractional shares will be issued; any fractional positions will be rounded up to the nearest whole share. Stockholders previously approved a proposal allowing the Board to set the ratio, which was chosen to support efforts to regain compliance with Nasdaq’s minimum bid price requirement.
BIO-key International, Inc. held a special stockholder meeting where investors approved an amendment to its Certificate of Incorporation to enable a reverse stock split of its common stock. The reverse split may be implemented at a ratio between 1-for-2 and 1-for-10.
The Board of Directors has discretion to decide whether to proceed, as well as the exact ratio and timing, but must act no later than May 6, 2026. At the meeting, 5,600,692 shares were represented, and the proposal passed with 4,209,160 votes in favor versus 1,361,166 against.
BIO-key International, Inc. reported that Nasdaq notified the company on April 16, 2026 that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it did not timely file its Annual Report on Form 10-K for the year ended December 31, 2025.
The company stated that this notification has no immediate effect on the listing or trading of its common stock on the Nasdaq Capital Market. BIO-key is working with its auditors to finalize the Form 10-K and announced that it expects to file the report next week.
BIO-key International outlined a strong outlook for the first half of 2026, expecting a 50% increase in first-half revenues and profitability for the period ending June 30, 2026. This improvement is driven by building software license momentum and stronger hardware sales.
The company highlighted a one-year software license renewal with a longstanding foreign retail bank and more than $1M in contracts for Pocket 10 Finger Scanners and Mobile POS Pro devices across the first two quarters. Management also pointed to larger biometric authentication opportunities with foreign government agencies and regulated enterprises, supported by a growing base of annually recurring software and services revenues.
BIO-key International, Inc. notified the SEC it cannot timely file its Annual Report on Form 10-K for the period ended December 31, 2025. The company cites incomplete compilation and review of certain financial statement items and expects to file on or before the fifteenth calendar day following the prescribed due date.
BIO-key International reported 2025 results showing lower revenue but a much stronger balance sheet, and outlined expectations for growth in 2026. Full-year 2025 revenue was $6,095,117, down about 12% from 2024, mainly due to a large bank renewal that favored 2024 and the exit from the Swivel Secure distribution agreement.
Hardware revenue more than doubled to $1,342,148 and services revenue rose to $1,172,107, but lower license fees pulled gross profit down to $4,722,080 with a 77.5% gross margin. The company reduced selling, general and administrative costs by 11%, yet its 2025 net loss widened slightly to $4,590,370, or $0.69 per share.
Cash and cash equivalents climbed to $2,694,663 at year-end 2025 from $437,604, and book value rose to $7,668,613, helped by $6,966,558 of warrant exercise proceeds and a $1,000,000 note. Management highlighted defense and financial-sector wins, including a $280,000 follow-on defense order and a $1,000,000 annual license renewal with a foreign bank, and expects top-line growth and improved bottom-line performance in 2026, with preliminary Q1 2026 revenue projected to grow 37% over Q1 2025. The company noted that the audit of its 2025 financial statements was not yet complete, so results are subject to change.
BIO-key International, Inc. is asking stockholders to approve an amendment to its Certificate of Incorporation to authorize a reverse stock split of its common stock at a ratio between 1-for-2 and 1-for-10. The board would choose whether to proceed, the exact ratio and the timing, any time up to May 6, 2026.
As of March 9, 2026, BIO-key had 10,849,618 common shares outstanding and 170,000,000 authorized. The company explains that a higher per-share price from the reverse split is intended to help it regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share; its stock last traded at $0.65 on March 13, 2026.
The split would affect all stockholders uniformly, so each investor should hold roughly the same ownership percentage afterward, with fractional shares rounded up to the nearest whole share. However, because the total authorized shares would remain unchanged, the transaction would significantly increase the number of authorized but unissued shares that could later be used for financings, acquisitions or equity incentives, which the company notes could have dilutive and potential anti-takeover effects.